Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia

Genes and Immunity

Volumn 16, Issue 1, 2015, Pages 83-88

  Schnetzke, U ^a   Spies Weisshart, B ^a   Yomade, O ^a   Fischer, M ^a   Rachow, T ^a   Schrenk, K ^a   Glaser, A ^a   Von Lilienfeld Toal, M ^a   Hochhaus, A ^a   Scholl, S ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CYTOGENETICS; FEMALE; GENOTYPE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION RISK; INFECTIOUS COMPLICATION; INNATE IMMUNITY; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; COMPLICATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; RETROSPECTIVE STUDY;

HUMANS; LEUKEMIA, MYELOID, ACUTE; PNEUMONIA; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SEPSIS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84921617658     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2014.67     Document Type: Article

References (40)

1. Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S et al. Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Med Oncol 2010; 27: 1037-1045.
2. Syrjala H, Ohtonen P, Kinnunen U, Raty R, Elonen E, Nousiainen T et al. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 2010; 29: 1211-1218.
3. Specchia G, Pastore D, Carluccio P, Mele G, Montagna MT, Liso A et al. Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Leuk Lymphoma 2003; 44: 97-101.
4. Hamalainen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences. Leuk Lymphoma 2008; 49: 495-501.
5. Rossini F, Verga M, Pioltelli P, Giltri G, Sancassani V, Pogliani EM et al. Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline-containing regimens. Haematologica 2000; 85: 1255-1260.
6. Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv Immunol 2011; 109: 87-124.
7. Brown KL, Cosseau C, Gardy JL, Hancock RE. Complexities of targeting innate immunity to treat infection. Trends Immunol 2007; 28: 260-266.
8. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-384.
9. Netea MG, Van der Graaf C, Van der Meer JW, Kullberg BJ. Recognition of fungal pathogens by Toll-like receptors. Eur J Clin Microbiol Infect Dis 2004; 23: 672-676.
10. Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW et al. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med 2008; 14: 346-352.
11. Ohto U, Yamakawa N, Akashi-Takamura S, Miyake K, Shimizu T. Structural analyses of human Toll-like receptor 4 polymorphisms D299G and T399I. J Biol Chem 2012; 287: 40611-40617.
12. Nachtigall I, Tamarkin A, Tafelski S, Weimann A, Rothbart A, Heim S et al. Polymorphisms of the toll-like receptor 2 and 4 genes are associated with faster progression and a more severe course of sepsis in critically ill patients. J Int Med Res 2014; 42: 93-110.
13. Sampath V, Mulrooney NP, Garland JS, He J, Patel AL, Cohen JD et al. Toll-like receptor genetic variants are associated with Gram-negative infections in VLBW infants. J Perinatol 2013; 33: 772-777.
14. Papadopoulos AI, Ferwerda B, Antoniadou A, Sakka V, Galani L, Kavatha D et al. Association of toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms with increased infection risk in patients with advanced HIV-1 infection. Clin Infect Dis 2010; 51: 242-247.
15. Van der Graaf CA, Netea MG, Morre SA, Den Heijer M, Verweij PE, Van der Meer JW et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006; 17: 29-34.
16. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359: 1766-1777.
17. Xiong Y, Song C, Snyder GA, Sundberg EJ, Medvedev AE. R753Q polymorphism inhibits Toll-like receptor (TLR) 2 tyrosine phosphorylation, dimerization with TLR6, and recruitment of myeloid differentiation primary response protein 88. J Biol Chem 2012; 287: 38327-38337.
18. Lee SO, Brown RA, Kang SH, Abdel-Massih RC, Razonable RR. Toll-like receptor 2 polymorphism and Gram-positive bacterial infections after liver transplantation. Liver Transpl 2011; 17: 1081-1088.
19. Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33: 638-644.
20. Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012; 205: 639-646.
21. Brown RA, Gralewski JH, Eid AJ, Knoll BM, Finberg RW, Razonable RR. R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins. Transplantation 2010; 89: 811-815.
22. Klostergaard A, Steffensen R, Moller JK, Peterslund N, Juhl-Christensen C, Molle I. Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: no impact of chitotriosidase and mannose-binding lectin polymorphisms. Eur J Haematol 2010; 85: 58-64.
23. Choi EH, Taylor JG, Foster CB, Walsh TJ, Anttila VJ, Ruutu T et al. Common polymorphisms in critical genes of innate immunity do not contribute to the risk for chronic disseminated candidiasis in adult leukemia patients. Med Mycol 2005; 43: 349-353.
24. Yomade O, Spies-Weisshart B, Glaser A, Schnetzke U, Hochhaus A, Scholl S. Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. Ann Hematol 2013; 92: 1071-1077.
25. Pabst S, Yenice V, Lennarz M, Tuleta I, Nickenig G, Gillissen A et al. Toll-like receptor 2 gene polymorphisms Arg677Trp and Arg753Gln in chronic obstructive pulmonary disease. Lung 2009; 187: 173-178.
26. Schroder NW, Hermann C, Hamann L, Gobel UB, Hartung T, Schumann RR. High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. J Mol Med (Berl) 2003; 81: 368-372.
27. Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H et al. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinare Vereinigung fur Intensiv-und Notfallmedizin (DIVI)). Ger Med Sci 2010; 8: Doc14.
28. Ahmad-Nejad P, Denz C, Zimmer W, Wacker J, Bugert P, Weiss C et al. The presence of functionally relevant toll-like receptor polymorphisms does not significantly correlate with development or outcome of sepsis. Genet Test Mol Biomarkers 2011; 15: 645-651.
29. Garnacho-Montero J, Garcia-Cabrera E, Jimenez-Alvarez R, Diaz-Martin A, Revuelto-Rey J, Aznar-Martin J et al. Genetic variants of the MBL2 gene are associated with mortality in pneumococcal sepsis. Diagn Microbiol Infect Dis 2012; 73: 39-44.
30. Arcaroli J, Silva E, Maloney JP, He Q, Svetkauskaite D, Murphy JR et al. Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med 2006; 173: 1335-1341.
31. Kumpf O, Giamarellos-Bourboulis EJ, Koch A, Hamann L, Mouktaroudi M, Oh DY et al. Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Crit Care 2010; 14: R103.
32. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010; 10: 131-144.
33. Chen LW, Chen PH, Hsu CM. Commensal microflora contribute to host defense against Escherichia coli pneumonia through Toll-like receptors. Shock 2011; 36: 67-75.
34. Yamamoto K, Ferrari JD, Cao Y, Ramirez MI, Jones MR, Quinton LJ et al. Type I alveolar epithelial cells mount innate immune responses during pneumococcal pneumonia. J Immunol 2012; 189: 2450-2459.
35. Schurr JR, Young E, Byrne P, Steele C, Shellito JE, Kolls JK. Central role of toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria. Infect Immun 2005; 73: 532-545.
36. Tang L, Li Q, Bai J, Zhang H, Lu Y, Ma S. Severe pneumonia mortality in elderly patients is associated with downregulation of Toll-like receptors 2 and 4 on monocytes. Am J Med Sci 2014; 347: 34-41.
37. Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23: 635-640.
38. Becker C, Ali HA, Krahl R, Poenisch W, Wedding U, Fiedler F et al. High complete remission rate in patients with acute myeloid leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group. ASH Annu Meet Abstr 2004; 104: Abstract 880.
39. Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res 2009; 127: 1-4.
40. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.